Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated?
A small number of patients exist with carcinoma of the pancreas with an inoperable but not metastasized tumor. Prospective randomized studies defined the standard of combined radiochemotherapy during the early 1980s for these patients. Since then, new drugs have shown considerable activity and in parallel improvements in radiotherapy treatment planning and delivery have been achieved. Therefore, it is time to ask whether patients with locally advanced, inoperable pancreatic cancer without metastases should still be irradiated or not. This review summarizes the current literature on combined radiochemotherapy for locally advanced carcinoma of the pancreas. Median survival times of 10-11 months and 1-year survival rates of about 40% can be achieved with modern radiochemotherapy regimens.
Wenz
Frederik
F
Department of Radiation Oncology, Mannheim Medical Center, University of Heidelberg, Germany. frederik.wenz@radonk.ma.uni-heidelberg.de
Tiefenbacher
Uta
U
Fuss
Martin
M
Lohr
Frank
F
D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis